(NASDAQ: SPRY) Ars Pharmaceuticals's forecast annual revenue growth rate of 62.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.44%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.17%.
Ars Pharmaceuticals's revenue in 2026 is $98,986,000.On average, 6 Wall Street analysts forecast SPRY's revenue for 2026 to be $14,347,335,294, with the lowest SPRY revenue forecast at $12,430,782,337, and the highest SPRY revenue forecast at $16,468,452,970. On average, 6 Wall Street analysts forecast SPRY's revenue for 2027 to be $25,790,050,174, with the lowest SPRY revenue forecast at $21,876,508,619, and the highest SPRY revenue forecast at $32,486,069,131.
In 2028, SPRY is forecast to generate $43,420,351,310 in revenue, with the lowest revenue forecast at $31,336,137,357 and the highest revenue forecast at $52,452,976,021.